GlycoNet is advancing research, innovation, and training in glycomics to improve the quality of life of Canadians.

GlycoNet is a one-stop global destination focused on developing new carbohydrate-based drugs, vaccines and diagnostics, in collaboration with academic and industry organizations to address areas of unmet need through applied glycomics research. This national platform supports translational research, protection of intellectual property, novel drug development, company formation and training of a new generation of glyco-scientists and entrepreneurs. The network includes over 170 researchers across Canada who focus on cancer, chronic diseases, infectious diseases, and neurodegenerative diseases.

GlycoNet is funded by the Government of Canada through the Networks of Centres of Excellence (NCE) Program.

0
Network Investigators
0
Trained HQP
0
Funded Projects
0
Network Partners

Latest News

Enzymes in bacteria found to have an unexpected taste for carbs

GlycoNet researchers studying complex enzymes gain insight into how some pathogens could potentially be targeted without antibiotics.

SARS-CoV-2 uses sugars to invade human cells, new study shows

Understanding the process could help scientists look out for new, more infectious variants, say GlycoNet researchers.

New anti-diabetic treatment approved for human trials

A natural compound that slows the breakdown of starch could be used to develop a more pleasant treatment for managing Type 2 diabetes.

Network Members

Canadian Glycomics Network
E5-33 Gunning/Lemieux Chemistry Centre
University of Alberta, T6G 2G2
Tel: 780-492-6204
Fax: 780-492-4147

Subscribe to GlycoNet’s Newsletter

© CANADIAN GLYCOMICS NETWORK (GLYCONET). ALL RIGHTS RESERVED.

en_USEnglish
Scroll to Top